secwatch / observer
8-K filed June 9, 2023, 7:59 PM ET ticker KYNB CIK 0000921299
other material confidence high sentiment neutral materiality 0.15

FibroGen shareholders elect Class III directors, approve say-on-pay and auditor ratification

KYNTRA BIO, INC.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

KYNTRA BIO, INC. shareholders approved Election of Class III directors at the 2023-06-07 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-06-07
Exact text from the filing
(i) Enrique Conterno: 67,436,799 shares of Common Stock voted for, 3,332,142 withheld, and 10,632,221 broker non-votes; (ii) Aoife Brennan, M.B., B.Ch.: 69,182,144 shares of Common Stock voted for, 1,586,797 withheld, and 10,632,221 broker non-votes; and (iii) Gerald Lema: 67,636,643 shares of Common Stock voted for, 3,132,298 withheld, and 10,632,221 broker non-votes.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

KYNTRA BIO, INC. shareholders approved Advisory vote on executive compensation at the 2023-06-07 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2023-06-07
Exact text from the filing
The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

KYNTRA BIO, INC. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-06-07 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-06-07
Exact text from the filing
78,505,537 shares of Common Stock voted for, 674,522 against, and 2,221,103 abstaining.
View on SEC.gov

546 shareholder votes filed in the last 30 days. Browse all shareholder votes →

KYNTRA BIO, INC. filing history →

Source: SEC EDGAR
accession 0000950170-23-027252
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.